

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/036445 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 31/282 (2006.01)
C07K 16/28 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/CN2024/112302

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

15 August 2024 (15.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/113147

15 August 2023 (15.08.2023) CN

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **BEIGENE SWITZERLAND GMBH**
[CH/CH]; Aeschengraben 27, Basel 4051 (CH).

(72) Inventor; and

(71) Applicant (for SC only): **MA, Yiyuan** [CN/CN]; No.
30 Science Park Road, Zhongguancun Life Science Park,
Changping District, Beijing 102206 (CN).

(72) Inventors: **QIN, Tai**; No. 30 Science Park Road, Zhong-
guancun Life Science Park, Changping District, Beijing
102206 (CN). **LEAW, Shiangjiin**; No. 30 Science Park
Road, Zhongguancun Life Science Park, Changping Dis-
trict, Beijing 102206 (CN). **ZHENG, Wenjuan**; No. 30
Science Park Road, Zhongguancun Life Science Park,
Changping District, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard
38, LinFengErLu Road, Greenland Central Square, Haidian
District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: TREATMENT OF LUNG CANCER WITH ANTI-PD-1 AND CHEMOTHERAPY

(57) Abstract: Provided is a treatment of lung cancer (in particular, small cell lung cancer) in a human subject with an anti-PD-1 antibody and, optionally, chemotherapy. In some embodiments, the small cell lung cancer is an advanced (e.g., locally advanced) or extensive stage (e.g., stage III or stage IV), unresectable or metastatic (e.g., with liver, lung or lymph node metastasis, e.g., with 2, 3 or more metastatic sites) lung cancer. In some embodiments, the chemotherapy is carboplatin and/or cisplatin, and optionally further etoposide. In some embodiments, the SCLC is small cell carcinoma. In some embodiments, the SCLC is combined small cell carcinoma. In some embodiments, the treatment is the first line treatment. In some embodiments, the claimed therapy is effective in the treatment of SCLC. In some embodiments, the human subject is a responder to treatment by at least one measure of response to treatment.



WO 2025/036445 A1